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Since Parodi1 first demonstrated in 1991 the fea-
sibility of aortic aneurysm exclusion via the endovas-
cular route, manufactured endoprostheses with a
variety of designs and implantation techniques have
been developed. Several clinical series have validated
the clinical feasibility and short-term efficacy of
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Purpose: The purpose of this study was to evaluate prospectively the results of the bifur-
cated Vanguard endovascular graft for abdominal aortic aneurysm (AAA) repair.
Methods: Seventy-five patients, with a median age of 69.6 years (range, 48 to 88 years) and
asymptomatic AAAs, were recruited in 14 French vascular institutions. An independent
committee validated the indications for endovascular repair, and all the implantations
were supervised by a well-trained medico-technical assistant. Further independent com-
mittees reviewed patient data, clinical data, and imaging follow-up examination. The
main endpoints were implantation success, mortality, morbidity, reinterventions, and
aneurysm evolution assessed with serial computed tomographic (CT) scanning.
Results: All the grafts were successfully implanted, resulting in a 100% success rate on an
intent-to-treat basis. At discharge, there were no deaths, six significant local complications
(8%) that necessitated surgery, no vascular complications, and six systemic complications
(8%). The average durations of intensive care unit and hospital stays were 26 ± 6 hours and
6 ± 2.54 days, respectively. Predischarge CT scan results showed five type I and 18 type II
endoleaks (total, 30%). At the end of the follow-up period (mean duration, 18.35 ± 4.12
months; range, 17 days to 24 months), seven patients (9%) had died: one from sepsis, five
from unrelated causes, and one from aneurysm rupture. The 2-year cumulative survival
rate was 86% ± 5.9%. Twenty-one subsequent endovascular or vascular procedures were
necessitated (28%) in 17 patients (23%) to treat graft limb occlusion or stenosis (n = 9
patients) or to seal an endoleak (n = 8 patients). The 2-year cumulative survival rate free
of reintervention was 67% ± 7%. On CT scans, the mean AAA diameter decreased from 54
mm ± 8.9 (range, 45 to 80 mm) before surgery to 51.6 mm ± 9.1 at 6 months and to 43.4
mm ± 4.4 at the end of the follow-up period (P = .001). Persistent endoleak was signifi-
cantly associated with an increase in diameter (4 of 5 [80%] vs 1 of 47 [2%]; P = .001).
Conclusion: In selected patients, the bifurcated Vanguard endovascular graft may be
implanted with a low mortality and morbidity rate and a favorable mid-term survival
rate. The decrease of the aneurysm size is a strong argument in favor of the efficiency of
the device. However, lasting endoleaks with increased aneurysm diameter and occur-
rence of limb graft stenosis or occlusion raise concerns and justify a careful long-term
follow-up monitoring of all patients who undergo treatment with endovascular tech-
nique. (J Vasc Surg 1999;30:209-18.)
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endovascular repair. Mortality rates ranged from 0 to
28%, with an early failure rate of 13% to 25% and a
persistent leak rate anywhere between 6% and 48%.2-4
Most of these series included the investigators’ initial
patients, who were usually at high surgical risk, and
several types of devices, including home-made and
first generation endovascular grafts.5
The Vanguard Endoaortic Graft (BP32 78184,
Boston Scientific Europe, St Quentin-en-Yuelines
Cedex, France) is a second generation, two-piece
modular graft. Its design is derived from the Stentor
system6 but with technologic improvements to the
polyester, the nitinol frame, the attachment of the
components, and the introducer sheath.
To evaluate the efficacy of this endoprosthesis, a
multicenter, prospective study was organized by a
group of French vascular surgeons and intervention-
al radiologists. To limit the learning curve effect,
surgical indications were verified by independent
experts and the implants were performed in the dif-
ferent centers under the supervision of a medico-
technical team with extensive experience in the pro-
cedure. The results were validated after review by a
second group of independent experts who had not
participated in the procedures.
This report presents the clinical results and the
computed tomographic (CT) scan evolution obtained
with the Vanguard endoluminal aortic graft in 75
patients with a mean follow-up period of 18.35 ±
4.12 months.
METHODS
Recruitment took place in 14 university or pri-
vate French hospitals, which were all qualified in
both the conventional and the endovascular repair of
aortic aneurysms. To avoid center bias, a maximum
of 15 procedures was allowed per center. The orga-
nization of the study, the centers, and the number of
procedures per center are shown in the Appendix.
Patient selection. All the patients who were
admissible in the study underwent a helical CT scan
and an angiogram to determine the critical arterial
lengths and diameters. The CT scans were performed
with 3-mm slices from the celiac artery to the external
iliac arteries with and without contrast. Angiography
was performed in frontal and lateral planes with a grad-
uated catheter. The medical records, angiograms, and
CT scans then were sent to one of the outside experts.
When there was a disagreement between the center
and the expert, the file was submitted to one of the
principal study coordinators for a final decision.
Patients could be included in the study when they
fulfilled the following conditions: age more than 18
years; a good to moderate surgical risk (American
Society of Anesthesia classification 1, 2, 3); abdominal
aortic aneurysm with an anteroposterior or lateral
diameter of at least 45 mm; presence of an infrarenal
neck of 15 mm or more in length; distance between
renal and internal iliac arteries at least 153 mm; diam-
eter of aortic neck between 18 and 25 mm; and diam-
eter of common iliac arteries no more than 12 mm.
The exclusion criteria were as follows: ASA 4 classifi-
cation or compassionate indication, Marfan’s syn-
drome, pregnancy, known allergy to nitinol, polyester
or contrast agents, active infection, and ruptured or
symptomatic aneurysms. Also excluded were cases of
aneurysm with a suprarenal or juxtarenal extension or
with an expected necessity for an iliac graft extension
covering patent internal iliac arteries, occlusion of the
superior mesenteric artery with a patent inferior
mesenteric artery, necessity for surgical reconstruction
of the visceral arteries, thrombus or major calcification
of the aneurysm’s neck, multistenosed iliac arteries,
iliac arteries with a diameter of less than 6 mm, and
greater than 90-degree angulation of the iliac arteries
or the proximal aneurysm neck.
The Ethics Committee of Henri Mondor Hospital,
Creteil, France, approved the protocol on September
30, 1996. After having received an explanation on the
innovative nature of this procedure, the possible
immediate benefits, and the uncertainty of the long-
term results, all the included patients gave their writ-
ten informed consent to participate in the study.
Deployment technique. The procedures were
performed either in operating rooms with portable
C-arms for image digitizing and videotape data
recording or in radiology suites with operating room
aseptic technique. All the procedures were per-
formed with general anesthesia with endotracheal
intubation. Arterial pressures were monitored via a
suitable catheter. The patients underwent prepara-
tion and draping for conventional surgery. The
implantation technique has been described else-
where.6 The delivery system consisted of 21F intro-
ducer sheaths that necessitated a femoral cut-down
for the aorto-iliac components and 12.5F introduc-
ers for the iliac components, which were placed per-
cutaneously. To avoid the possibility of covering the
internal iliac arteries, the shorter of the two available
lengths of endoprosthesis (153 mm) was more com-
monly used. Iliac extensions were used when the
device limbs were too short or to seal a distal
endoleak. At the end of the procedure, completion
angiography was performed with a pigtail catheter
positioned cephalad to the upper extremity of the
endoprosthesis to detect proximal leaks and then
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with retrograde injection through the femoral intro-
ducers to detect distal leaks. Delayed images were
obtained in all the cases. Pressure was not measured
in the aneurysm sac itself, and neither the lumbar
nor the inferior mesenteric arteries were pre-
embolized. Thrombogenic agents were not injected
into the sac. None of the procedures was monitored
with intravascular ultrasound scanning.
During the procedure, the patients were given
0.5 mg/kg of heparin before femoral clamping and
prophylactic antibiotic therapy consisting of 2 g of
intravenous cefamandole. During the postoperative
period, the patients were administered a low molec-
ular weight heparin, usually Fragmin (5000 U/day;
Upjohn, St Quentin les Yuelines, France), during the
length of the hospital stay, followed by aspirin (250
mg/day) at discharge and thereafter. Postoperative
clinical management and particularly the need for
intensive care monitoring were left to the discretion
of the patient physicians.
Postoperative evaluation. Before discharge, all
the patients underwent abdominal CT scanning
with contrast. Laboratory tests, including complete
blood counts and clinical chemistry, were performed
daily during hospitalization. After discharge, the
patients returned for follow-up examination at 1, 3,
and 6 months, with subsequent visits planned at 12
months and then annually for 5 years. Each visit
comprised clinical evaluation and duplex scan exam-
ination. CT scans with contrast were performed at
6-month intervals or earlier if previous tests revealed
evidence of a leak. Angiograms were obtained in
case of persistent endoleak on CT scanning. All rel-
evant information was collected prospectively in the
case report form provided by the EUROSTAR
Registry7 and subsequently was validated by a clini-
cal research assistant.
Clinical events were reviewed from the patient’s
medical records and verified by two independent
experts who did not participate in the study (one
vascular surgeon, one angiologist). Similarly, CT
scan and angiogram results were reviewed by anoth-
er two independent experts (interventional radiolo-
gists). When there was a disagreement between the
investigator and the experts, a third expert judge-
ment (interventional radiologist) was sought and the
majority opinion was adopted.
The clinical data and complications were classified
according to the Society for Vascular Surgery/
International Society for Cardiovascular Surgery def-
initions,8 and the endoleaks were classified according
to the White/May definitions, with type I endoleaks
representing perigraft or graft-related endoleaks and
type II endoleaks representing retrograde flow into
the aneurysm sac, non-graft related.9 Decisions on
the type of endoleak were made by the experts after
examination of the CT and angiogram data.
End points and statistical analysis. The pri-
mary study endpoints were implantation success,
mortality, morbidity, and reinterventions. A compar-
ison of pre-procedure CT scan results with the 6-
month and most recent CT scan results also assessed
evolution of the aneurysm’s diameter and endoleaks.
Statistical analysis, with the Stateview software
(Abacus Concepts, Inc, Berkeley, Calif), included
the c 2 test, the Student t test, and life-table analysis.
RESULTS
From October 1996 to June 1997, 75 patients
were entered into the study and 71 patients fullfilled
the specific inclusion criteria. However, four patients
were incorrectly included in the study: one patient
with a chronic aneurysm rupture, one patient whose
condition was classified as ASA 4, and two patients
with iliac artery diameters, as assessed with table
angiography, more than 12 mm wider than the pre-
procedure measurements. During the same period
of time, the participating centers have treated 15
additional patients with different devices, which are
not included in the current analysis.
The 75 patients consisted of five women and 70
men, with a mean age of 69.6 ± 8.64 years (range,
48 to 88 years). Table I presents the preoperative
risk factors. Eight patients (11%) were classified as
ASA 1, 38 (51%) were ASA 2, 28 (37%) were ASA
3, and one was ASA 4.
The aneurysms were limited to the aorta in 11
cases (14.7%) and the aortoiliac in 64 cases (85.3%). In
the latter group, 42 (56%) involved the aortic bifurca-
tion, 21 (28%) involved the proximal part of one or
both common iliac arteries, and one (1.3%) was closed
to the ostium of one hypogastric artery. The mean
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Table I. Preoperative risk factors in 75 patients
who underwent treatment with the Vanguard
endovascular graft
Risk factors No. of patients (%)
Heart disease 43 (57.7)
Hypertension 45 (60)
Chronic obstructive 
pulmonary disease 23 (30.7)




aneurysm diameter was calculated for 74 patients,
excluding the patient with a contained chronic rupture
who had a total aneurysm diameter and including the
periaortic hematoma of 150 mm. The mean maximum
diameter was 54.0 ± 8.9 mm (range, 45 to 80 mm).
The mean aortic neck diameter measured 21.6 ± 2.3
mm, and the mean iliac neck diameters were 11.1 ±
1.4 mm (range, 7 to 13 mm), with a median of 11
mm. The mean infrarenal aortic neck length was 28.5
± 11 mm (range, 15 to 68 mm). The inferior mesen-
teric artery was occluded in 45 (60%) of the cases, the
right internal iliac artery in three cases (4%), and the
left internal iliac artery in one case (1%).
All the grafts were successfully implanted, and
during the peri-operative period, there were no surgi-
cal conversions, which represents a 100% success on
an intent-to-treat basis. The intraoperative data are
shown in Table II. The most prevalent Vanguard
device size was the 26/12 mm by 153 mm and was
used in 42 patients (56%). Distal extensions with the
Passager (Boston Scientic) endoprosthesis were nec-
essary in 36 patients (48%), bilaterally in 16 cases, uni-
laterally in 20 cases, and with a proximal cuff in one
case (1.3%). Additional endovascular or surgical pro-
cedures were necessary in 12 cases (16%) to improve
access, to repair a femoral artery injury, or to treat an
intraoperative limb graft occlusion (Table III).
In five patients (7%), the proximal nitinol scaf-
fold, not covered with polyester, was placed across
the ostia of the renal arteries. In one patient, one of
the renal arteries thrombosed without any clinical
consequences. Another patient had chronic renal
failure (400 m mol/L creatinine level) and an arterial
hypertension related to microembolization to both
kidneys develop. In two other patients, renal polar
arteries were covered by the covered portion of the
endoprosthesis. These arteries thrombosed without
clinical or laboratory consequences. In another four
patients, a patent internal iliac artery was covered
without clinical consequences.
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Table II. Intraoperative data of Vanguard
endovascular graft implantations in 75 patients
Duration of procedure (minutes) 124.5 ± 40.3 (60 to 260)
Fluoroscopy time (minutes) 30.1 ± 16.1 (9 to 104)
Contrast volume (mL) 212 ± 79 (90 to 500)
Units of blood transfused 0
Table III. Additional intraoperative procedures
during the Vanguard endovascular graft implanta-
tions in 75 patients
No. of procedures (%)
Proximal cuff 1 (1)
Additional Passager 36 (48)
Iliac angioplasty 7 (9)
Femoral patch angioplasty 3 (4)
Femorofemoral graft 2 (2)
Fig 1. Cumulative survival rate curve of 75 patients with abdominal aortic aneurysms treated
with Vanguard endovascular graft.
None of the patients required a blood transfu-
sion during the procedure. However, in one patient,
difficulties with introduction of the delivery system
led to a blood loss of 800 mL, which necessitated
the transfusion of 2 units of packed red blood cells
on the second postoperative day.
Pre-discharge results. None of the patients
died during the hospitalization, resulting in a hospi-
tal mortality rate of 0%. In-hospitalization data are
shown in Table IV.
The patients’ mean recorded temperatures were
37.1°C (0.61 ± SD) at day 0, 37.8°C (0.62 ± SD) at
day 1, 37.7°C (0.62 ± SD) at day 2, and 35.5°C
(0.63 ± SD) at day 3, falling to 37.3°C (0.63 ± SD)
at day 6. The mean post-implant hematocrit and
platelet counts were 40 ± 4.9% and 160 · 109/L,
respectively. C-reactive protein levels were 144.33 ±
73 mg/L. The immediate mean post-implant serum
creatinine level was 82.3 ± 54 m mol/L.
Six post-implant general complications (8%)
were observed. These consisted of three cardiac
complications (two myocardial infarctions and one
case of heart failure), which were treated medically
without serious clinical sequelae, two pulmonary
complications that rapidly resolved, and one case of
renal insufficiency (serum creatinine level, 400
m mol/L, previously described). The frequency of
local complications was 17% (13 cases), but only six
of these (8%) necessitated surgical treatment. The
local complications were one hemorrhage, two
hematomas, two false aneurysms, and one dehis-
cence of the surgical wound.
Pre-discharge CT scan and angiogram revealed
the presence of 23 endoleaks (30%), including five
type I and 18 type II. Among the five type I leaks,
one occurred at the proximal neck, two at the distal
iliac end of the graft, one from the graft body, and
one at the graft body-iliac limb junction. The proxi-
mal neck leak was the results of a deployment that
was too distal. The distal leaks were the result of a
mismatch between the diameters of the device limbs
and the iliac arteries in two of the four patients who
initially did not meet the inclusion criteria.
Follow-up examination. The mean follow-up
period was 18.35 ± 4.12 months for the entire series.
One patient was lost to follow-up examination after
his 6-month follow-up CT scan, which showed no
leak. For surviving patients, the minimum and maxi-
mum follow-up period was 10 and 25 months,
respectively. Fig 1 shows the survival curve of the 75
patients. There was a total of seven deaths (9%) dur-
ing the entire follow-up period. One patient died of
sepsis at 18 days after implantation, resulting in a 1-
month mortality rate of 1.3%. This was an 88-year-
old patient classified as ASA III who had undergone
an uncomplicated procedure and was discharged on
day 6. The patient had to be rehospitalized on day 10
with a septic picture and blood cultures positive for
Staphylococcus aureus and subsequently died of mul-
tiple organ failure. One 82-year-old patient died of
an aneurysm rupture 10 months after repair. The
implant procedure had been uncomplicated, but the
angiogram results before discharge revealed a type II
endoleak. Doppler ultrasound scan results at 4
months did not reveal any persistent endoleak, and
CT scan without contrast results at 6 months did not
show an increase in aneurysm size. At 10 months, the
patient was hospitalized with a retroperitoneal rup-
ture of the aneurysm and died despite emergency
surgery. Examination of the explanted endoprosthe-
sis showed a 3-mm hole on the posterior surface of
the graft near the crotch. There were also ruptures of
polypropylene ties, which attached the nitinol wires.
The remaining deaths were caused by pulmonary
cancer in two cases and cardiac diseases in three cases.
Excluding reoperation for aneurysm rupture,
eight vascular graft related complications occurred
(10.6%). These complications are listed in Table V
with the vascular and endovascular procedures that
were performed during the surveillance period of the
study. Of note is that all graft-related vascular compli-
cations occured on the controlateral iliac limb graft
side. Intercurrent general events included two
episodes of angina pectoris treated medically, one
pneumonia treated with antibiotics, and one severe
renal failure caused either by nephrosclerosis or by
crystalline cholesterol embolism in a patient with
patent renal arteries. Because of concern about a renal
artery stenosis in this patient, a left aorto-renal bypass
grafting procedure was performed at 6 months, with
some improvement of renal function. Fig 2 shows a
life-table analysis of the survival rate free of redo
endovascular and vascular reinterventions to maintain
graft patency or aneurysm exclusion.
Aneurysm evolution. Sixty-eight scans were
available at the 3-month follow-up period, 64 were
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Table IV. In-hospitalization data after the Vanguard
endovascular graft implantations in 75 patients
Mean intubation time (hour) 3.8 ± 14
Mean intensive care unit stay (hour) 26.5 ± 39
Mean hospital stay (day) 6.6 ± 25
Return to normal feeding (day) 1.2 ± 1
Return to normal walking (day) 2.4 ± 1.6
available at the 6-month follow-up period, 63 of
which were performed with contrast, and 52 were
available between 12 and 24 months.
Outcome of endoleaks. There were five type I
endoleaks at discharge. All were sealed at the end of
the follow-up period. The proximal aortic endoleak
was successfully treated with a 26/50 mm cuff at 6
months. The transprosthetic leak and the stump
junction leak sealed spontaneously. The two distal
iliac endoleaks were treated with bilateral Passager
endoprostheses, one successfully and the other
unsuccessfully. This later patient then underwent
successful treatment with an iliac wrapping through
a retroperitoneal incision. At the end of the follow-
up period, two more patients had new type I
endoleaks develop. One patient with iliac enlarge-
ment is awaiting treatment. The remaining patient
died of rupture as previously mentioned.
Of the 18 initial type II leaks, 11 (61%) closed
spontaneously (mean time, 4.5 months). Three
patients underwent bilateral embolization of the
lumbar arteries via the internal iliac arteries. One of
these procedures was twice unsuccessful, and the
endoleak resumed. In one more patient, a new type
II endoleak was detected at 6 months and success-
fully treated with lumbar embolization. Thus, at the
end of the follow-up examination, 14 of a total of 19
type II endoleaks (73%) were sealed and one persist-
ed: four awaited CT scan examination.
Evolution of aneurysm diameter. At 6 months,
aneurysm diameters were calculated from the 63 scans
available, excluding the chronic rupture. The mean
diameter was 51.6 ± 9.1 mm, for a mean reduction of
2.3 mm. The diameter was unchanged in 43 patients
(68%), increased by 3 mm in three patients (4.7%),
and decreased by at least 3 mm in 17 patients (27%).
At the end of the follow-up period, the mean diame-
ter calculated from the 52 CT scans available from the
latest examination between 12 and 24 months was
43.4 mm ± 4.4, from 55.25 ± 6.5 before surgery (P
= .001). The diameter remained unchanged in seven
patients (13%), decreased in 39 (75%), and increased
in six (11%). Increase of aneurysm diameter was
observed in four of the five patients with a persistent
leak (80%) and in one of 47 patients who did not have
a detected leak (2%; P = .001).
DISCUSSION
This study represents a realistic assessment,
under optimal conditions, of the current results on
the exclusion of abdominal aortic aneurysm by the
Vanguard endoprosthesis.
This multicenter study was conducted with an
independent evaluation of the key findings. To cir-
cumvent the learning curve effect, patient selection
was in all cases validated by an expert and the teams
who performed the procedures were fully trained
and supervised. The admission of four patients out-
side the inclusion criteria was the result of a misun-
derstanding of the case with the contained aneurysm
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Fig 2. Cumulative survival rates free of vascular and endovascular reinterventions of 75
patients with abdominal aortic aneurysms treated with Vanguard endovascular graft.
rupture, to the imprecision of the ASA 4 classifica-
tion in a patient with chronic obstructive pulmonary
disease, and to two instances of a discrepancy
between the preprocedure and table angiogram
measurements of the common iliac artery diameters.
Nevertheless, these patients have all been included
in the analysis. Of note, the two latter patients had
type I endoleaks that necessitated subsequent
endovascular treatment. Also importantly, the study
was restricted to the second generation bifurcated
Vanguard endoprosthesis, conforming in terms of
design and quality assurance to the requirements of
the European Community Mark.
In these selected patients, graft implantation was
a relatively easy task, which is reflected by the short
duration of the procedure and fluoroscopy time. In
12 cases (16%), technical difficulties arose. Seven
access problems (13%) were solved with iliac angio-
plasty, three common femoral artery lacerations
were solved with patch angioplasty, and two limb
graft occlusions were solved with femorofemoral
bypass grafting. Deployment difficulties (9.5%),
including renal artery coverage, were more demand-
ing and, in one case (1.3%), resulted in renal artery
emboli that ultimately led to renal insufficiency.
Nevertheless, there was no surgical conversion,
resulting in 100% success of implantation on an
intent-to-treat basis. Immediate conversions whose
rate could be as high as 25%4 are generally per-
formed if it proves impossible to introduce or deploy
the endoprosthesis, if there is an arterial perforation
or an unresolvable covering of the renal arteries by
the device fabric, or, more commonly, if there is the
inability to exclude the aneurysm. Surgical conver-
sion is associated with increased mortality,10 espe-
cially in patients at high surgical risk.
The low necessity for transfusion was notable. In
contrast to other systems, particularly custom-made
devices, the Vanguard system offers hemostatic
sheaths resulting in minimal blood loss. With cus-
tom-made aortouniiliac tube grafts, Yusuf et al3
reported an average blood loss of 500 mL with a
maximum of 1500 mL. Broeders11 estimated blood
loss at 300 mL with the Endovascular Technology
system, and White et al12 reported a mean of 556
mL with various endoprostheses.
Operative mortality and complications were low
with no deaths during the post-implant hospitaliza-
tion and only one death during the first month
(1.3%). Thirty percent of the patients did not
require intensive care monitoring, and the average
hospital stay was 6 days. In contrast to the MinTec
Stentor (La Ciotat, France) graft, any post-proce-
dure elevations in patient’s temperatures were small
and no clotting disorders were noted.6,13 In the
absence of a clear explanation, one may hypothesize
that pyrogens were present on the late Stentor graft.
A recent literature review has shown that con-
ventional surgery has a mortality rate between 3.1%
and 7.8%,14 and our findings confirm the seemingly
less aggressive nature of endovascular approach-
es.15,16 However, most of the patients included in
our study were considered to be good surgical risks
with favorable anatomies, long proximal aneurysm
JOURNAL OF VASCULAR SURGERY
Volume 30, Number 2 Becquemin et al 215
Table V. List of open or endovascular procedures during follow-up period of 75 patients who underwent
treatment with a Vanguard endovascular graft
Procedures No. of procedures Causes Results
Balloon angioplasty 2 Graft stenosis (1) Successful (2)
Iliac stenosis (1)
Balloon angioplasty + stent 3 Graft stenosis (3) Successful (3)
Thrombolysis + Passager 1 Graft occlusion and limb disconnection Successful (1)
Femorofemoral graft 1 Graft occlusion Successful (1)
Limb-graft recanalization 1 Graft occlusion Successful (1)
Surgical conversion 1 AAA rupture Death
Lumbar embolization 5 (4 pts) Type II endoleak Successful (3)
Failure (2; 1 pt)
Aortic cuff 2 Type I proximal endoleak (1) Successful (2)
Neck enlargement (1)
Iliac Passager 4 (2 pts) Type I distal endoleak Successful (3)
Failure (1)




AAA, Abdominal aortic aneurysm; pt, patient.
necks, and no involvement of the internal iliac arter-
ies. In these types of patients, the operative mortali-
ty rate with conventional surgery is at its lowest.
There are several nonrandomized, comparative
studies of endovascular repair and open surgery.
White et al12 found in two groups of 28 and 29
patients a similar mortality and incidence of systemic
complications (37% vs 29%) but a higher incidence of
vascular complications in the endovascular group
(15% vs 25%). In the endovascular group, they
observed less bleeding (mean, 873 mL vs 1422 mL)
and a shorter intensive care unit stay (mean, 1.8 days
vs 0.7 days). Comparable mortality for the open and
endovascular repair groups was confirmed in an
updated series by the same team (5.6% in both
groups).17 In a study of two groups of 30 patients,
Brewster et al18 reported a reduction in blood loss
(mean, 498 mL vs 1287 mL), time spent in intensive
care (mean, 0.1 days vs 1.8 days), length of hospital-
ization (3.9 days vs 10.3 days), and systemic compli-
cations (4% vs 18%). Mortality in both groups was 0,
despite two conversions to conventional repair. In a
comparative series of 44 patients, Hölzenbein et al19
also reported a shorter hospital stay (mean, 5.6 days
vs 13.3 days) and a 14% reduction in hospitalization
costs despite the higher cost of the endovascular pro-
cedure itself.
The long-term results of endovascular grafting
are not known because the technique is recent and
the technology is rapidly evolving. In this series, the
2-year cumulative survival rate was 86%, which com-
pares favorably with the long-term results of open
surgery.20,21 However, the comparative, nonran-
domized, study results of May et al17 found no sta-
tistically significant differences in the survival rates
between open and endovascular repair with 2-year
survival rates of 92% and 88%, respectively.
Early and late leakage is the principal problem
associated with endovascular aneurysm repair. In our
series, the pre-discharge endoleak rate was 30%,
which is within the range of 10% to 47% reported in
the literature.4,22 Although it has been reported
that, even in the presence of an endoleak, an exclud-
ed aneurysm increases at a slower rate than an
untreated aneurysm,23 persistent leaks may lead to
rupture.5,18,22 This was observed in one of our
patients. In our series, early type I leaks were relative-
ly few (6%) and were mostly related to errors in
patient selection or device deployment. This under-
scores the need for the strict observance of patient
inclusion criteria and expertise in the procedure itself.
Secondary type I endoleak as the result of longitudi-
nal sutures rupture, as reported with the Stentor sys-
tem,6,13 were not observed in this series. However,
the one case with a hole observed post mortem in the
Vanguard fabric, which may have been caused by
material fatigue, gave rise to concern. Finally, we
observed only one case of a new type I distal endoleak
as the result of iliac enlargement. Type II leaks can be
either immediate or delayed and may resolve sponta-
neously,6,23 as we observed in 11 (61%) of our cases.
Five times in four patients, we attempted to occlude
the fourth pair of lumbar arteries with microcatheter-
ization of the vessel ostium via the internal iliac arter-
ies. Durable occlusion was achieved with injection of
glue in three patients. Walker and Hopkinson24 and
Brewster et al18 have reported that coil embolization
or injection of absorbable gelatin sponge into the sac
can facilitate thrombosis. However, we do not have
any experience with this method.
We observed a slight decrease in mean aneurysm
size after 6 months, which was significant at the final
follow-up examination, therefore supporting the
efficiency of this therapeutic concept. The effect of
persistent endoleaks on the increase in aneurysm size
and rupture was significant in our series and con-
firms the findings of May et al26 and Broeders et
al.27 This fact underlines the absolute necessity for a
long-term monitoring and treatment of endoleak,
especially in large aneurysms.
The design and configuration of the Vanguard
graft may be a matter for discussion. The advantage
of anatomic reconstruction with a bifurcated endo-
prosthesis over unilateral tube endografts plus a
crossover femoral artery bypass graft has not been
formally shown, although, with the latter, the mor-
tality, the need for conversion or laparotomy, and
the overall morbidity can reach up to 3.5%, 13%, and
13.3%, respectively.3 Unilateral tube endoprostheses
have the advantage of being more versatile and can
be used in a wider range of patients.4 However,
occlusion of the contralateral iliac artery is not
always a simple task. Two groin incisions are neces-
sitated and, therefore, pose a greater risk of infec-
tion. Furthermore, thromboses of the femoro-
femoral crossover are not uncommon.
The lack of large diameter endografts is an obvi-
ous limit of the Vanguard system. During patient
recruitment for this study, the device range was
restricted to 20-mm to 26-mm aortic diameters and
10-mm to 12-mm iliac diameters. Currently, aortic
diameters up to 30 mm and iliac extension compo-
nents up to 14 mm are available. However, some
patients require even larger diameter devices. A coni-
cal graft with an adjustable diameter would be a use-
ful addition to the product line to treat patients with
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associated large iliac arteries. Graft length rarely poses
a problem because the modular design allows exten-
sions to be used as needed. More than half of the
patients in our study required iliac or aortic exten-
sions. However, it should be noted that some patients
were rejected during recruitment because the distance
between the renal and internal iliac arteries was less
than the minimum device length of 153 mm.
The ongoing status of the endograft limbs and
iliac arteries is an important consideration. In this
series, we observed eight device limb stenoses or
occlusions during the follow-up period. A hypothet-
ical cause of kinking is longitudinal compression of
the endograft during retraction of the aneurysm sac.
The effectiveness of a metallic scaffold support over
the entire length of the endoprosthesis to prevent
graft kinking is debatable. In reports of the EVT sys-
tem in which the polyester is unsupported, this
question has not been fully evaluated.22,23 Chuter et
al,27 on the other hand, report successful prophylax-
is of kinking at the limb-body junction of a similar
unsupported endoprosthesis by stenting during the
procedure junction between the body of the endo-
prosthesis. The contralateral iliac limb is also a criti-
cal point in modular systems. Of note, all the graft
stenoses or occlusions occurred in the contralateral
iliac limb graft, leading to some suspicions concern-
ing the role of the junction in the formation of
thrombus. In the long run, the modular component
exposes also to late disconnection of the contralater-
al limb,28 which we observed in our series. The risk
of disconnection may be increased by an inadequate
overlap or by changes in aneurysm geometry over
time. Disconnection results in late leaks and contin-
ued pressurization of the sac.
In conclusion, the bifurcated Vanguard endovascu-
lar graft gave highly satisfactory early results in the
treatment of abdominal aortic aneurysm in well-
defined indications and implant conditions. However,
one of the seven late deaths was caused by an
aneurysm rupture. In addition, persistent or new
endoleaks and delayed vascular or graft-related com-
plications were not uncommon. As a result, long-term
scrutinity of all endovascular grafts is justified to detect
potentially hazardous conditions. Finally, long-term
observations and comparative studies of different
endografts will be necessary to define the optimal graft
design.
We thank Dr Alexi Laurent for his help in the statistical
analysis, Dr Alexandre d’Audiffret for reviewing the manu-
script, and Boston Scientific, which provided the grafts and
supported financially the monitoring of the study.
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